Actavis and Biotin
February 2, 2012
ACTAVIS has signed a partnership
deal with biotechnological
company Bioton, for the
development and registration of
insulins, including analogue
insulins.
Under the agreement Biotin will
develop and manufacture the
products, whilst Actavis will be
granted an exclusive license to
commercialise those products
under the Actavis brand
throughout the European Union
and the United States of America,
as well as several other European
countries.
In addition, Bioton has also
signed memoranda of
understanding with Actavis for the
sale of insulins in 24 additional
territories, including Australia.
“The recombinant- and analogue
insulins alone should add around
EUR 900 million (USD 1.2 billion) to
our enterprise value,” said Actavis
CEO Claudio Albrecht.
“Thanks to the collaboration
agreement with Bioton, we will be
among the leading manufacturers
of insulin, including analogue
insulins,” he added.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Feb 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Feb 12
